15.96 USD
▲+0.15+4.18%
2026-08-03
市值
$973.31M
市盈率
—
EPS
-1.84
股息率
—
52 周区间
12.12 – 35.34
成交量
564.66K
Beta
2.51
目标价
37.19
52W 低 12.1252W 高 35.34
价格走势
公司简介
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008...